Challenges and New Directions in Therapeutic Cancer Vaccine Development
Danjie Pan,
Jiayang Liu,
Xuan Huang,
Songna Wang,
Kudelaidi Kuerban,
Yan Yan,
Yi Zhun Zhu,
Li Ye
Affiliations
Danjie Pan
Laboratory of Drug Discovery from Natural Resources and Industrialization, School of Pharmacy, Macau University of Science and Technology, Macau 999078, China
Jiayang Liu
Department of Biological Medicines, School of Pharmacy, Fudan University, Shanghai 201203, China
Xuan Huang
Department of Biological Medicines, School of Pharmacy, Fudan University, Shanghai 201203, China
Songna Wang
Laboratory of Drug Discovery from Natural Resources and Industrialization, School of Pharmacy, Macau University of Science and Technology, Macau 999078, China
Kudelaidi Kuerban
Department of Biological Medicines, School of Pharmacy, Fudan University, Shanghai 201203, China
Yan Yan
Laboratory of Drug Discovery from Natural Resources and Industrialization, School of Pharmacy, Macau University of Science and Technology, Macau 999078, China
Yi Zhun Zhu
Laboratory of Drug Discovery from Natural Resources and Industrialization, School of Pharmacy, Macau University of Science and Technology, Macau 999078, China
Li Ye
Laboratory of Drug Discovery from Natural Resources and Industrialization, School of Pharmacy, Macau University of Science and Technology, Macau 999078, China
Tumor vaccine is a promising immunotherapy for solid tumors. Therapeutic tumor vaccines aim at inducing tumor regression, establishing durable antitumor memory, and avoiding non-specific or adverse reactions. However, tumor-induced immune suppression and immune resistance pose challenges to achieving this goal. In this article, we review multiple challenges currently faced in the development of therapeutic tumor vaccines, with a particular focus on anonymous antigen vaccines in situ as a new direction. We summarize the research progress in this area, aiming to provide a reference for future studies on tumor vaccines.
